Approval Marks Pivotal Expansion of HIV Prevention Options in the United States.
On December 20th, the U.S. Food and Drug Administration (FDA) announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.